-
September 19, 2011
Blue Cross parent's profits drop in second quarter
After surging earlier in the year, profits of the parent of Blue Cross & Blue Shield of Illinois dropped sharply during the second quarter, to a still hefty $270 million, as benefits rose and membership shrank.
Read More
-
September 7, 2011
J&J's prostate drug Zytiga gets final nod in Europe
Another new prostate cancer drug will soon hit the market in Europe. Regulators there approved Johnson & Johnson's Zytiga pill as a second-line treatment, after a fast-track review.
Read More
-
September 7, 2011
J&J's prostate drug Zytiga gets final nod in Europe
Another new prostate cancer drug will soon hit the market in Europe. Regulators there approved Johnson & Johnson's Zytiga pill as a second-line treatment, after a fast-track review.
Read More
-
August 20, 2011
There's an App for that Cold
As a physician, it’s not uncommon for Dr. Trevor Satterfield to meet with patients who can remember what a pill looks like, but the name escapes them. That’s where his iPhone has become his best friend.
Read More
-
August 19, 2011
Roche Seeks Win on Heart Pill Where Pfizer Failed
Roche Holding AG (ROG) may get the first signs at a cardiology conference this month that the Swiss drugmaker can garner $6.8 billion in sales with a pill to combat heart disease by raising so-called good cholesterol.
Read More
-
August 19, 2011
MDD Market Snapshot: Depressing Future For Antidepressants
Although a significant portion of the U.S. population, approximately 6.5% or 15 million adults annually suffers from depression, the antidepressant drug market is on the decline and sales are expected to decrease further over the next two years as two of the largest products on the market face patent expirations.
Read More
-
August 17, 2011
For Pharma, FDA Is Elephant in Facebook Comment Room
On Monday, Facebook began requiring pharmaceutical brand pages to enable comments, as expected. Yet, although pharma marketers are fearful of regulatory reaction to a potential flood of comments, some don't see Facebook as the big villain in the story. It's the Food and Drug Administration that's raised the most ire.
Read More
-
August 15, 2011
Pharma-Page Facebook Commenters, Start Your Engines
Social media can be a minefield for pharma companies given the FDA’s requirements to keep product information fairly balanced and promote only approved uses of drugs.
Read More
-
August 10, 2011
Disappointing Provenge Sales Stir Doubts About Demand
Dendreon Corp. withdrew its yearly sales forecast for the new prostate cancer immunotherapy Provenge on August 3, shocking Wall Street, and raising concerns about whether the high-profile company had hit a speed bump - or mountain.
Read More
-
July 26, 2011
Life after the small molecule
Since 2006 the growth of biologics has outstripped small molecules, and this trend is set to continue. So is the biologic the latest silver bullet? Or are the associated costs enough for pharma to put on the brakes?
Read More
-
July 26, 2011
Biosimilar Insulin Worth The Effort? For Some, Maybe
With most eyes fixed on the imminent arrival of biosimilar antibodies – billed as the most valuable copy-cat biologics, given originators' high prices – it may be easy to overlook the potential of first-generation biosimilars such as insulin.
Read More
-
July 22, 2011
Cisco Cius Android Tablets Go to Work on San Diego Hospital Private Cloud
In advance of the July 31 launch of the Cisco Cius enterprise Android tablet, Palomar Pomerado Health System in San Diego has deployed the Cius in a pilot trial to enable doctors to access mobile health applications from a private cloud.
Read More
-
July 14, 2011
iPad EHR developer DrChrono secures $675K
DrChrono, one of the few electronic health records (EHR) vendors to offer an EHR built from the ground up for the Apple iPad, has raised $675,000 in seed funding, according to a report in TechCrunch.
Read More
-
July 13, 2011
Are Americans becoming cyberchondriacs?
When it comes to getting sick, many of us want answers right away. So it's no wonder why statistics show more people are logging on to get them.
Read More
-
July 12, 2011
FDA Approval Of Xarelto Bodes Well For Drug's Future Expansion
The July 1 approval of Johnson & Johnson 's novel anticoagulant Xarelto for prevention of deep vein thrombosis is an important step for J&J and its ex-U.S. partner Bayer AG as they gear up to play in the highly promising but increasingly complicated world of novel anticoagulants.
Read More